Reggio Emilia (Northern Italy) Interdisciplinary Uveitis Clinic: What We Have Learned in the Last 20 Years

被引:0
|
作者
Gentile, P. [1 ,2 ]
Aldigeri, R. [3 ]
Mastrofilippo, V. [2 ]
Bolletta, E. [2 ]
De Simone, L. [2 ]
Gozzi, F. [2 ]
Ragusa, E. [4 ]
Ponti, L. [4 ]
Adani, C. [2 ]
Zanelli, M. [5 ]
Belloni, L. [6 ]
Bonacini, M. [6 ]
Croci, S. [6 ]
Zerbini, A. [6 ]
De Maria, M. [7 ]
Neri, A. [7 ]
Vecchi, M. [7 ]
Cappella, M. [8 ]
Fastiggi, M. [8 ]
De Fanti, A. [9 ]
Citriniti, G. [10 ]
Crescentini, F. [10 ]
Galli, E. [10 ,11 ]
Muratore, F. [10 ,11 ]
Montepietra, S. [12 ]
Contardi, G. [13 ]
Massari, M. [13 ]
Paci, M. [14 ]
Facciolongo, N. C. [15 ]
Beltrami, M. [16 ]
Cavallini, G. M. [11 ]
Salvarani, C. [10 ,11 ]
Cimino, L. [2 ,11 ]
机构
[1] Univ Modena & Reggio Emilia, Clin & Expt Med PhD Program, Modena, Italy
[2] Azienda USL IRCCS Reggio Emilia, Ocular Immunol Unit, Viale Risorgimento 80, I-42123 Reggio Emilia, Italy
[3] Univ Parma, Dept Med & Surg, Parma, Italy
[4] Univ Modena & Reggio Emilia, Inst Ophthalmol, Modena, Italy
[5] Azienda USL IRCCS Reggio Emilia, Pathol Unit, Reggio Emilia, Italy
[6] Azienda USL IRCCS Reggio Emilia, Clin Immunol Allergy & Adv Biotechnol Unit, Reggio Emilia, Italy
[7] Azienda USL IRCCS Reggio Emilia, Ophthalmol Unit, Reggio Emilia, Italy
[8] Azienda USL IRCCS Reggio Emilia, Pediat Rheumatol Unit, Reggio Emilia, Italy
[9] Azienda USL IRCCS Reggio Emilia, Santa Maria Nuova Hosp, Pediat Unit, Reggio Emilia, Italy
[10] Azienda USL IRCCS Reggio Emilia, Rheumatol Unit, Reggio Emilia, Italy
[11] Univ Modena & Reggio Emilia, Dept Surg Med Dent & Morphol Sci, Interest Transplants Oncol & Regenerat Med, Modena, Italy
[12] Azienda USL IRCCS Reggio Emilia, Neuromotor & Rehabil Dept, Neurol Unit, Reggio Emilia, Italy
[13] Azienda USL IRCCS Reggio Emilia, Infect Dis Unit, Reggio Emilia, Italy
[14] Azienda USL IRCCS Reggio Emilia, Thorac Surg Unit, Reggio Emilia, Italy
[15] Azienda USL IRCCS Reggio Emilia, PulmonolUnit, Reggio Emilia, Italy
[16] Azienda USL IRCCS Reggio Emilia, Med & Gastroenterol Unit, Reggio Emilia, Italy
关键词
Biological; idiopathic; infectious; ocular inflammation; uveitis; TERTIARY REFERRAL CENTER; 1ST; 3000; PATIENTS; ENDOGENOUS UVEITIS; SYSTEMIC CORTICOSTEROIDS; EPIDEMIOLOGY; PATTERNS; POPULATION; DIAGNOSIS; BLINDNESS; CRITERIA;
D O I
10.1080/09273948.2023.2296617
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To analyze the referral patterns and the clinical and therapeutic features of patients diagnosed with uveitis in an Italian tertiary referral center to provide a comparison with previously published series from the same center.Methods: Retrospective retrieval of data on all new referrals to the Ocular Immunology Unit in Reggio Emilia (Italy) between November 2015 and April 2022 and comparison with previously published series from the same center.Results: Among the 1557 patients, the male-to-female ratio was 1:1.27. Anterior uveitis was the most common diagnosis (53.7%), followed by posterior (21.6%), pan- (18.5%), and intermediate (6.2%) uveitis. The most identifiable specific diagnoses were anterior herpetic uveitis (18.4%), Fuchs uveitis (12.8%), and tuberculosis (6.1%). Infectious etiologies were the most frequent (34.1%) and were more diffuse among non-Caucasian patients (p < 0.001), followed by systemic disease-associated uveitis (26.5%), and ocular-specific conditions (20%). Idiopathic uveitis accounted for 19.4% of cases. Fuchs uveitis presented the longest median diagnostic delay (21 months). Immunosuppressants were administered to 25.2% of patients. Antimetabolites, calcineurin inhibitors, and biologicals were prescribed to 18.4%, 3%, and 11.4% of cases, respectively. Compared to our previous reports, we observed a significant increase in foreign-born patients and in infectious uveitis, a decrease in idiopathic conditions, and an increasing use of non-biological and biological steroid-sparing drugs.Conclusions: The patterns of uveitis in Italy have been changing over the last 20 years, very likely due to migration flows. Diagnostic improvements and a more widespread interdisciplinary approach could reduce the incidence of idiopathic uveitis as well as diagnostic delay.
引用
收藏
页码:1777 / 1787
页数:11
相关论文
共 50 条
  • [21] Good Dying in the Elderly: What Have We Learned in the Last Ten Years?
    Mejia Grueso, Andrea
    Ramirez Pazos, Jeronimo
    Roldan Bernal, Maria Camila
    Lopez Sanmiguel, Andrea
    Alejandro Velasquez, Dario
    UNIVERSITAS MEDICA, 2022, 63 (04):
  • [22] What we have learned on Flash memory reliability in the last ten years
    Cappelletti, P
    Bez, R
    Modelli, A
    Visconti, A
    IEEE INTERNATIONAL ELECTRON DEVICES MEETING 2004, TECHNICAL DIGEST, 2004, : 489 - 492
  • [23] What have we learned from cancer immunotherapy in the last 3 years?
    Ascierto, Paolo A.
    Marincola, Francesco M.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12
  • [24] Diabetic foot infections: what have we learned in the last 30 years?
    Uckay, Ilker
    Aragon-Sanchez, Javier
    Lew, Daniel
    Lipsky, Benjamin A.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2015, 40 : 81 - 91
  • [26] MUSCLE BIOPSY - WHAT HAVE WE LEARNT IN THE LAST 20 YEARS
    BAYLY, WM
    HODGSON, DR
    EQUINE VETERINARY JOURNAL, 1991, 23 (03) : 150 - 151
  • [27] Neoadjuvant Therapy - What Have We Achieved in the Last 20 Years?
    Huober, Jens
    von Minckwitz, Gunter
    BREAST CARE, 2011, 6 (06) : 419 - 426
  • [28] Metabolomics 20years on: what have we learned and what hurdles remain?
    Alseekh, Saleh
    Fernie, Alisdair R.
    PLANT JOURNAL, 2018, 94 (06): : 933 - 942
  • [29] 20/21: WHAT HAVE WE LEARNED?
    Paredes, Sebastian
    ARQ, 2021, (107): : 150 - 151
  • [30] The Day One Talk, 20 Years Later: What Have We Learned?
    Mack, Jennifer W.
    JCO ONCOLOGY PRACTICE, 2023, 19 (04) : 164 - +